Back to User profile » Dr Tomoko Yamagishi
Papers published by Dr Tomoko Yamagishi:
Drug-induced interstitial lung disease in the treatment of malignant lymphoma as a potential diagnostic marker: a comparison of serum Krebs von Lungen-6 and thymus and activation-regulated chemokine/CC chemokine ligand 17
Yamane H, Ochi N, Nagasaki Y, Yamagishi T, Honda Y, Nakagawa N, Takeyama M, Nakanishi H, Takigawa N
Therapeutics and Clinical Risk Management 2018, 14:1457-1465
Published Date: 21 August 2018
Circulating thymus and activation-regulated chemokine/CC chemokine ligand 17 is a strong candidate diagnostic marker for interstitial lung disease in patients with malignant tumors: a result from a pilot study
Yamane H, Ochi N, Yamagishi T, Honda Y, Takeyama M, Takigawa N
Therapeutics and Clinical Risk Management 2015, 11:949-959
Published Date: 17 June 2015
Docetaxel for non small cell lung cancer harboring the activated EGFR mutation with T790M at initial presentation
Yamane H, Ochi N, Yasugi M, Tabayashi T, Yamagishi T, Monobe Y, Hisamoto A, Kiura K, Takigawa N
OncoTargets and Therapy 2013, 6:155-160
Published Date: 6 March 2013